-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Glofitamab in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Glofitamab in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Glofitamab in Follicular Lymphoma Drug Details: Glofitamab (Columvi) is a bispecific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tobemstomig in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tobemstomig in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tobemstomig in Triple-Negative Breast Cancer (TNBC) Drug Details: RG-6139...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Repotrectinib in Uterine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Repotrectinib in Uterine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Repotrectinib in Uterine Cancer Drug Details: Repotrectinib (Augtyro) acts as an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Radspherin in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Radspherin in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Radspherin in Epithelial Ovarian Cancer Drug Details: Radspherin is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Bladder Cancer Drug Details: ORM-5029 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Lung Cancer Drug Details: Atezolizumab (Tecentriq) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Neuroendocrine Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atezolizumab in Neuroendocrine Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Neuroendocrine Cancer Drug Details: Atezolizumab (Tecentriq) is an antineoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Entrectinib in Metastatic Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Entrectinib in Metastatic Uveal Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Entrectinib in Metastatic Uveal Melanoma Drug Details: Entrectinib (Rozlytrek) belongs...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Anal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isunakinra in Anal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Anal Cancer Drug Details: Isunakinra (EBI-005) was under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Selinexor in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Selinexor in Osteosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Selinexor in Osteosarcoma Drug Details: Selinexor (Xpovio, Nexpovio) is an antineoplastic agent....